Top Markets
#1 ADO Protocol ADO Protocol +194.72%
#2 Islamic Coin Islamic Coin +155.37%
#3 GoPlus Security GoPlus Security +40.11%
#4 GAIB AID GAIB AID +24.67%
#5 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +19.15%
#6 TENDIES TENDIES +16.67%
#7 Wrapped NXM Wrapped NXM +14.87%
#8 Verus Coin Verus Coin +13.64%
#9 Tutorial Tutorial +13.32%
#10 Pons Pons +12.61%
Coin of the day
ADO Protocol ADO Protocol
Configuración
Idioma
ESPAñOL
Moneda
USD
Tema
Vectus Biosystems Limited Vectus Biosystems Limited

Vectus Biosystems Limited

VBS
Clasificación en acciones #33546
Vectus Biosystems Limited, an Australian medical research and development firm,... Vectus Biosystems Limited, an Australian medical research and development firm, specializes in devising therapies for fibrotic conditions and hypertension. Its pharmaceutical pipeline addresses ailments affecting the heart, kidneys, liver, and lungs. The company's leading experimental drug, VB0004, aims to counter the degradation of functional tissue resulting from fibrosis, scarring, and elevated blood pressure. Furthermore, Vectus intends to advance treatments for hepatic fibrotic diseases, such as non-alcoholic steatohepatitis, and various pulmonary fibrotic disorders. Beyond its therapeutic endeavors, the company also provides AccuCal and RealCount software, tools engineered to enhance the swiftness and precision of DNA and RNA quantification in laboratory settings. Established in 2005, Vectus Biosystems is headquartered in Rosebery, Australia.
Precio por acción
$0.11989842
Capitalización bursátil
$7.42M
Cambio (1 día)
6.25%
Cambio (1 año)
179.27%
País
AU
Comercio Vectus Biosystems Limited (VBS)

Categoría

Healthcare
Ingresos de Vectus Biosystems Limited (VBS)
Ingresos en Aug 2026 TTM: 0
Según los últimos informes financieros de Vectus Biosystems Limited, los ingresos actuales de la empresa (TTM) son 0. En 2026, la empresa obtuvo unos ingresos de 0 igual a los ingresos del año 2026, que fueron de 0. Los ingresos representan la cantidad total que una empresa genera por la venta de bienes o servicios. A diferencia de las ganancias, no se restan los gastos.
Historial de ingresos de Vectus Biosystems Limited desde 2026 hasta 2026
Ingresos al final de cada año
Año Ingresos Cambiar
Not enough data for the provided dates.
Ingresos de empresas similares o competidoras
Empresa Ingresos Diferencia de ingresos País
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE